المنشورات طباعة Brooks TR, Zabor EC, Bedelu YB, Yang X, Karimi YH, Nedved AN, Wang Y, Dave N, Landsburg DJ, Baron K, Hu B, Trotier DC, Pophali PA, Miller J, Grover N, Reinert C, Major A, Schwarz T, Patel K, Salafian K, Ayers E, Sundaram S, Brody JD, McKenna M, Ryu Tiger YK, Sears-Smith M, Ghosh N, Peterson C, Khan C, Bliven SP, Narkhede M, Gibson A, Kline J, Munoz J, Garza-Morales R, Ho CI, Smith SD, Niu A, Hernandez-Ilizaliturri F, Chinyengetere F, Dave S, Abdel-Razeq N, Moustafa MA, Caimi PF, Hill BT. Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab. Blood. 2025 Oct 30; 146(18):2177-2188. View PubMed St-Pierre F, Bhatta S, Doukas PG, Jenkin M, Annunzio K, Rojek AE, Gibson A, Tiger YK, McCall B, Alhamad K, Hansen A, Alderuccio JP, Adewale O, Patel K, Trabolsi A, Lossos IS, Fitzgerald L, Ollila TA, Matasar MJ, Kline J, Karmali R, Epperla N. Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma-Results from a multicenter cohort study. Blood Cancer J. 2025 Jun 21; 15 (1):110 Epub 2025 June 21 View PubMed Andrew 1, Bradley 1, Jonathan 1, Reed 3, Alma 4, Marshall 5, Jordan 6, Kimberly 7, Rachel 8, Gina 8, Prerna 8, Muhammad 6, Christopher 3, Yun 5, Nausheen 6, Abdullah 4, Hamza 9, Barry 3, Shebli 3, Al-Ola 6, Hira 3. Talquetamab in heavily pretreated patients with multiple myeloma, including BCMA-refractory Blood Immunology & Cellular Therapy. 2025; 1(1). Epub 2025 Apr 04. Deevyashali, Yun, Kevin, Justin, Maroun, Shahzad. Updates on Therapeutic Strategies in the Treatment of Relapsed/Refractory Multiple Myeloma Cancers. 2024; 16(17):2931. McKenna M, Ryu Tiger YK, Rutherford SC, Evens AM. The Management of older patients with Hodgkin lymphoma: implications of S1826. Semin Hematol. 2024 Aug; 61 (4):236-244 Epub 2024 June 04 View PubMed Parsons SK, Rodday AM, Upshaw JN, Scharman CD, Cui Z, Cao Y, Tiger YKR, Maurer MJ, Evens AM. Harnessing multi-source data for individualized care in Hodgkin Lymphoma. Blood Rev. 2024 May; 65:101170. Epub 2024 Jan 14. View PubMed Habib MH, Tiger YKR, Dima D, Schlogl M, McDonald A, Mazzoni S, Khouri J, Williams L, Anwer F, Raza S. Role of Palliative Care in the Supportive Management of AL Amyloidosis-A Review. J Clin Med. 2024 Mar 29; 13 (7) View PubMed Evens AM, McKenna M, Ryu Tiger YK, Upshaw JN. Hodgkin lymphoma treatment for older persons in the modern era. Hematology Am Soc Hematol Educ Program. 2023 Dec 8; 2023 (1):483-499 View PubMed Ted B. Piorczynski, Yun Kyoung Ryu, Manuel A. Pazos, Wenxuan Huang, Seda S. Tolu, B. Estrella, J. Amengual. Combination Epigenetic Therapy Using YF2, a First-in-Class Histone Acetyltransferase Activator, Restores Immunogenicity in Diffuse Large B-Cell Lymphoma Blood. 2023. Seda S. Tolu, Ted B. Piorczynski, Manuel Pazos, Estrella Brian, Huang Wenxuan, Ryu Yun Kyoung, Cherng Hua-Jay J., Pro Barbara, Amengual Jennifer E.. JAK1/2 Inhibition Modulates Key Markers of Lymphomagenesis in 9p24.1 Amplified Lymphoma, Priming for Enhanced Antigenicity Blood. 2023; 142:6118. Manuel Pazos II, Estrella Brian , PhD, Piorczynski Ted B. , PhD, Tolu Seda S. , MD, Huang Wenxuan, Ryu Yun Kyoung , MD, PhD, Amengual Jennifer E , MD. First-in-Class HAT Activator (YF2) Combined with JAK/STAT Inhibitor (ruxolitinib) Unveils Potential Novel Treatment Approach for HDAC Inhibitor-Resistant CTCL Blood. 2023; 142:4184. Pazos MS, Estrella Brian, Piorczynski Ted, Tolu Seda, Huang Wenxuan, Ryu Yun, Amengual Jennifer. Combined with JAK/STAT Inhibitor (ruxolitinib) Unveils Potential Novel Treatment Approach for HDAC Inhibitor-Resistant CTCL Blood. 2022; 140:358-9. Ryu YK, Ricker EC, Soderquist CR, Francescone MA, Lipsky AH, Amengual JE. Targeting CD38 with Daratumumab Plus Chemotherapy for Patients with Advanced-Stage Plasmablastoid Large B-Cell Lymphoma. J Clin Med. 2022 Aug 22; 11 (16) View PubMed Ricker Edd C, Ryu Yun Kyoung, Amengual Jennifer E.. Daratumumab Plus Chemotherapy Induces Complete Responses in a Consecutive Series of Four Patients with Plasmablastic Lymphoma Blood. 2021; 138:4573. Chiarella AM, Ryu YK, Manji GA, Rustgi AK. Extracellular ATP and Adenosine in Cancer Pathogenesis and Treatment. Trends Cancer. 2021 Aug; 7 (8):731-750 Epub 2021 May 29 View PubMed Wong W, Alouani E, Wei A, Ryu YK, Chabot JA, Manji GA. Future of immunotherapy in pancreas cancer and the trials, tribulations and successes thus far. Semin Oncol. 2021 Feb; 48 (1):57-68 Epub 2021 Apr 17 View PubMed Rimmer K, Farber R, Thakur K, Braverman G, Podolsky D, Sutherland L, Migliore C, Ryu YK, Levin S, De Jager PL, Vargas W, Levine L, Riley CS. Fatal COVID-19 in an MS patient on natalizumab: A case report. Mult Scler J Exp Transl Clin. 2020 Jul-Sep; 6 (3):2055217320942931 Epub 2020 Aug 10 View PubMed Mema E, Cho E, Ryu YK, Jadeja P, Wynn R, Taback B, Ha R. In the Setting of Negative Mammogram, Is Additional Breast Ultrasound Necessary for Evaluation of Breast Pain? Curr Probl Diagn Radiol. 2019 Mar-Apr; 48 (2):117-120 Epub 2018 Jan 09 View PubMed Kang E, Jiang D, Ryu YK, Lim S, Kwak M, Gray CD, Xu M, Choi JH, Junn S, Kim J, Xu J, Schaefer M, Johns RA, Song H, Ming GL, Mintz CD. Early postnatal exposure to isoflurane causes cognitive deficits and disrupts development of newborn hippocampal neurons via activation of the mTOR pathway. PLoS Biol. 2017 Jul; 15 (7):e2001246 Epub 2017 July 06 View PubMed Kang E, Berg DA, Furmanski O, Jackson WM, Ryu YK, Gray CD, Mintz CD. Neurogenesis and developmental anesthetic neurotoxicity. Neurotoxicol Teratol. 2017 Mar-Apr; 60:33-39 Epub 2016 Oct 14 View PubMed Ryu YK, Mathena RP, Lim S, Kwak M, Xu M, Mintz CD. Sevoflurane Impairs Growth Cone Motility in Dissociated Murine Neurons. J Neurosurg Anesthesiol. 2016 Oct; 28 (4):405-412 View PubMed Patel A, Yamashita N, Ascano M, Bodmer D, Boehm E, Bodkin-Clarke C, Ryu YK, Kuruvilla R. RCAN1 links impaired neurotrophin trafficking to aberrant development of the sympathetic nervous system in Down syndrome. Nat Commun. 2015 Dec 14; 6:10119 View PubMed Jiang D, Lim S, Kwak M, Ryu YK, Mintz CD. The changes of oligodendrocytes induced by anesthesia during brain development. Neural Regen Res. 2015 Sep; 10 (9):1386-7 View PubMed Kwak M, Lim S, Kang E, Furmanski O, Song H, Ryu YK, Mintz CD. Effects of Neonatal Hypoxic-Ischemic Injury and Hypothermic Neuroprotection on Neural Progenitor Cells in the Mouse Hippocampus. Dev Neurosci. 2015; 37 (4-5):428-39 Epub 2015 June 13 View PubMed Wagner M, Ryu YK, Smith SC, Patel P, Mintz CD. Review: effects of anesthetics on brain circuit formation. J Neurosurg Anesthesiol. 2014 Oct; 26 (4):358-62 View PubMed Ryu YK, Khan S, Smith SC, Mintz CD. Isoflurane impairs the capacity of astrocytes to support neuronal development in a mouse dissociated coculture model. J Neurosurg Anesthesiol. 2014 Oct; 26 (4):363-8 View PubMed Huang L, Xiao A, Choi SY, Kan Q, Zhou W, Chacon-Heszele MF, Ryu YK, McKenna S, Zuo X, Kuruvilla R, Lipschutz JH. Wnt5a is necessary for normal kidney development in zebrafish and mice. Nephron Exp Nephrol. 2014; 128 (1-2):80-8 Epub 2014 Nov 19 View PubMed Ryu YK, Collins SE, Ho HY, Zhao H, Kuruvilla R. An autocrine Wnt5a-Ror signaling loop mediates sympathetic target innervation. Dev Biol. 2013 May 1; 377 (1):79-89 Epub 2013 Feb 27 View PubMed Ho HY, Susman MW, Bikoff JB, Ryu YK, Jonas AM, Hu L, Kuruvilla R, Greenberg ME. Wnt5a-Ror-Dishevelled signaling constitutes a core developmental pathway that controls tissue morphogenesis. Proc Natl Acad Sci U S A. 2012 Mar 13; 109 (11):4044-51 Epub 2012 Feb 17 View PubMed Armstrong A, Ryu YK, Chieco D, Kuruvilla R. Frizzled3 is required for neurogenesis and target innervation during sympathetic nervous system development. J Neurosci. 2011 Feb 16; 31 (7):2371-81 View PubMed Kaye RA, Ryu YK, Arora SR, Tabor SL, Döring J, Sun Y, Baldwin TD, Campbell DB, Chandler C, Cooper MW, Gerbick SM. Transition strengths and degree of deformation in 79 Sr Physical Review Journal. 2007; 75(3). PST-20592023 الصفحة الرئيسية المنشورات